Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.61 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.56 |
| ▸ | PI4KA | P42356 | 8/20 | 0.53 |
| ▸ | PI4K2B | Q8TCG2 | 8/20 | 0.53 |
| ▸ | PI4K2A | Q9BTU6 | 8/20 | 0.53 |
| ▸ | PI4KB | Q9UBF8 | 8/20 | 0.53 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42314 | 0.79 | ADORA2A (0.66) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL1059581 | 0.78 | NUDT1 (0.68) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL842440 | 0.76 | ADORA2A (0.61) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL31096982 | 0.76 | ADORA2A (0.61) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL31096975 | 0.76 | ADORA2A (0.61) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL42335 | 0.76 | ADORA2A (0.61) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL31096978 | 0.76 | ADORA2A (0.61) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL843169 | 0.76 | ADORA2A (0.61) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL8566 | 0.76 | ADORA2A (1.00) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL30962317 | 0.76 | ADORA2A (0.61) | ADORA2AADORA1NUDT1PI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257360-A1 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | UNIV OKLAHOMA (US) | 2025-08-14 | — | — | US | claimed |
| CN-113151261-B | Antisense oligonucleotides as inhibitors of TGF-R signaling | 神经视觉医药有限公司 | 2025-06-17 | — | — | CN | claimed |
| US-20240294924-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-09-05 | — | — | US | claimed |
| CN-117795071-A | Antisense oligonucleotides for preventing renal dysfunction caused by endothelial dysfunction through inhibition of ephrin-B2 | 马克斯·普朗克科学促进学会 | 2024-03-29 | — | — | CN | claimed |
| EP-4330397-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-03-06 | — | — | EP | claimed |
| WO-2023196944-A2 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2023-10-12 | — | — | WO | claimed |
| WO-2022263569-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-12-22 | — | — | WO | claimed |
| EP-4105328-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-12-21 | — | — | EP | claimed |
| US-20220143071-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | Neurovision Pharma GmbH (DE) | 2022-05-12 | — | — | US | claimed |
| CN-113151261-A | Antisense oligonucleotides as inhibitors of TGF-R signaling | 神经视觉医药有限公司 | 2021-07-23 | — | — | CN | claimed |
| US-6001577-A | SCREENING FOR LIGANDS ASSOCIATED WITH A DISEASE BY DETECTING LIGAND THAT PHOTOCROSSLINKS TO TARGET WITH PHOTOREACTIVE GROUPS FROM CANDIDATE MIXTURE, REMOVING ANY NUCLEIC ACIDS WITH AFFINITIES NOT ASSOCIATED WITH DISEASE, AND AMPLIFYING | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-12-14 | — | — | US | claimed |
| EP-0898575-A2 | A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | KÖSTER, Hubert (US) | 1999-03-03 | — | — | EP | claimed |
| EP-0736105-A4 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: PHOTOSELECTION OF NUCLEIC ACID LIGANDS AND SOLUTION SELEX | UNIV RESEARCH CORP (US) | 1998-10-28 | — | — | EP | claimed |
| US-5763177-A | SELEX IS AN ACRONYM FOR SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT; USEFUL FOR DIAGNOSIS AND/OR TREATMENT OF DISEASES OR PATHOLOGICAL OR TOXIC STATES | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-06-09 | — | — | US | claimed |
| EP-0828750-A1 | PALLADIUM CATALYZED NUCLEOSIDE MODIFICATION METHODS USING NUCLEOPHILES AND CARBON MONOXIDE | NeXstar Pharmaceuticals, Inc. (US) | 1998-03-18 | — | — | EP | claimed |
| US-5719273-A | GENETIC ENGINEERING | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-02-17 | — | — | US | claimed |
| WO-1997041139-A2 | A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | KOESTER HUBERT (US) | 1997-11-06 | — | — | WO | claimed |
| WO-1996038460-A1 | PALLADIUM CATALYZED NUCLEOSIDE MODIFICATION METHODS USING NUCLEOPHILES AND CARBON MONOXIDE | NEXSTAR PHARMACEUTICALS, INC. (US) | 1996-12-05 | — | — | WO | claimed |
| EP-0736105-A1 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: PHOTOSELECTION OF NUCLEIC ACID LIGANDS AND SOLUTION SELEX | NeXstar Pharmaceuticals, Inc. (US) | 1996-10-09 | — | — | EP | claimed |
| WO-1995008003-A1 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: PHOTOSELECTION OF NUCLEIC ACID LIGANDS AND SOLUTION SELEX | UNIVERSITY RESEARCH CORPORATION (US) | 1995-03-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143071-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | TGFBR1, TGFBR2, TGFB1 | ADORA2A 1258/4885ADORA1 689/4885NUDT1 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.